BZYR: Potential long term investment - with risk

15 янв. 2023 г.

I've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts:
1 - Introduction
2 - The historical battles
3 - Efficacy of a cancer treatment
4 - Summary
5 - The risk to reward for long term investors.
The above cannot possibly avoid referring to organisations and materials in the public domain - as matters of fact and truth before the courts.

Introduction:
The founder has discovered a treatment for cancers that cannot be treated by conventional treatments, that is better than anything out there at this time. The research has been in the public domain for the last 30-odd years. The discovery is called Antineoplastons - which is a combination of various peptides and other 'chemicals'.

Historical battles:
The research evidence for efficacy has not been faulted. The FDA (in the public domain) took the founder through 4 grand juries. The case failed at the Texas State Supreme Court, in an attempt to remove the founder's medical licence.

The whole story runs very deep back to the 1980s - but despite strenous efforts to shut down the treatment (and the founder), it persists to this day, through the endless legal battles. Staying within the 'House Rules' means that I am cautious not to breach.

In 1982 the FDA stated [they] "never have and never will approve a new drug to an individual but only to a large pharmaceutical firm with unlimited finances." Therefrom sprung one of the most severe fights in FDA history. [The founders] dealings with the FDA commenced in 1983 at that point the FDA commenced a civil action to try to close the clinic and stop all patients from receiving the medicine before the judge in this case.

Before the judge in the 1983 court case had announced her ruling the FDA sends her a letter warning her in advance "if this court declines to grant the injunction sought by the government thus permitting continued manufacture and distribution of antineoplastons the government would then be obliged to pursue other less efficient remedies such as actions for seizure and condemnation of the drugs or criminal prosecution of individuals."

Efficacy of cancer treatment with Antineoplastons:
Mainstream cancer research organisations will say "There is not enough reliable evidence to use it as a cancer treatment" or that the treatment is 'experimental'. But this is not true. If there has been an experiment, it was fully under the watch of the FDA, and the results are beyond belief for success.

Double-blind randomised controlled trials in Japan have proved the superior efficacy of the treatment (which is not 100% but far better than what exists).

Summary
Antineoplaston treatment has weathered all battles for over 30 years. It's not going away. It's survival suggests something novel and unique has been discovered. Why is this treatment surviving at all? Why all the battles against it? Those are matters for you to ponder.

The risk to reward for long term investors:
The weeky chart will show that BZYR (an OTC stock) is near rock bottom and possibly in an accummulation phase. Note carefully that OTC stocks are not on conventional exchanges like NYSE and NASDAQ.

The potential growth over a 5 year period could be significant in relation to a fixed risk of loss which should be an affordable one, if more research confirms it's specific kind of efficacy. This could be the next 'Amazon' of the biomedical world.

As always I emphasise the risk - and I am unable to provide tips on how to manage that. Disclaimers apply.